Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 7686 results

  1. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development [GID-TA11561] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  4. Direct skeletal fixation of limb prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  5. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490

    Awaiting development [GID-TA11624] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Violence and Aggression: short-term management in mental health, health and community settings

    In development [GID-NG10432] Expected publication date: TBC

    NICE guideline
    In development

  7. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  8. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  9. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  11. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  12. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: 31 March 2025

    Health technology evaluations
    In development

  13. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  14. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

    Awaiting development [GID-IPG10412] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  15. Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults

    In development [GID-IPG10411] Expected publication date: 06 August 2025

    Interventional procedures guidance
    In development